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Hepatitis case-finding among migrants in primary care: HepFree needs to be implemented  
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Childhood HBV vaccination and antenatal screening are two of the most important public health 
interventions for preventing and controlling chronic HBV infection worldwide1.  Even in countries 
with endemically low prevalence HBV vaccination is cost-effective when given as part of a 
hexavalent vaccine (DTaP/Hib/IPV/HepB) in the routine infant immunisation programme2, and 
antenatal screening to identify mothers with chronic HBV and then follow-up and immunise the 
infant is likely to be cost-saving3.  In the UK the majority of chronic HBV cases are in adults – 
predominantly migrants – who were infected in their country of origin (largely from countries where 
chronic HBV is over 2% in the population)4.  In contrast, the majority of HCV infections in the UK are 
in people who inject or have injected drugs though migrant populations also have an elevated risk of 
HCV infection compared to general population5.  
The next critical intervention is case-finding – and it makes sense to combine HBV and HCV testing.  
The National Institute for Health and Care Excellence  (NICE) recommends that “GPs and practice 
nurses should offer testing for hepatitis B and C to adults and children at increased risk of infection, 
particularly migrants from medium- or high-prevalence countries” 
(https://www.nice.org.uk/Guidance/PH43)  reinforced by Public Health England migrant health 
guide (https://www.gov.uk/topic/health-protection/migrant-health-guide).  The original 
recommendation was not based on direct trial evidence but economic models of potential 
interventions with a range of assumptions on HBV / HCV prevalence, intervention cost, uptake and 
engagement with specialist services6.  
This has now changed.  HepFree [Please Link to Paper] has transformed the evidence base.  HepFree 
is a complex intervention – by which we mean it has multiple ingredients – an algorithm on primary 
care systems, some compensation to GPs to take part and introduce the algorithm, a standard letter 
inviting patients for screening, and specialist clinical support for the practice.  The main study found 
convincing evidence that HepFree could a) increase uptake of viral hepatitis screening and linkage to 
care, b) identify a population with a higher than average risk of viral hepatitis, and c) be highly cost-
effective - at ~£8500 per Quality Adjusted Life Year – and well below suggested cost-effectiveness 
thresholds of average cost of NHS interventions7. 
HepFree found no evidence for a subsidiary question that this patient group prefer community 
based treatment over standard hospital based care whereas community care is critical to scaling up 
HCV treatment among PWID. 
It is a shame that the intervention was capped in some practices (ostensibly to save resources) with 
large numbers of potentially eligible patients, as we need to know both what it will cost in the real 
world and how these practices will cope with the intervention.  Nonetheless the evidence is 
compelling and strong enough to recommend implementation and moving to phase IV evaluation.  
‘Treatment as usual’ is failing to screen migrant populations – in the HepFree control less than 2% of 
patients were screened – and other studies also have shown low levels of screening except for 
pregnant women (because there  is a commissioned universal antenatal HBV screening programme 
in the UK)8.  Local commissioners and primary care services need help on how to take forward NICE 
guidance.  HepFree provides the immediate solution.   
There are a number of tweaks, however, that may be necessary.  First, in our commentary we focus 
in the first sentence on HBV because it is the most important cause of chronic viral hepatitis in 
migrant populations but HepFree screens for both HBV and HCV and the HepFree algorithm 
identifies “eligible patients” based on “ethnic group” rather than country of birth.  Two of us are 
from ethnic groups that maybe targeted by the algorithm though we were born in UK and US and 
consequently have a very low risk of HBV or HCV.  Country of birth, if routinely recorded on GP 
systems, will provide a greater yield9 and likely to be more cost-effective in the long run.  The 
proportion of chronic HCV infections found in the study population was not much higher than 
expected in the general population5.  Second, we need to monitor testing and specialist referral 
uptake to determine whether extra interventions or ingredients are required to attract patients into 
care who do not respond to the first invitation.  Third, cost-effectiveness will vary depending on 
chronic HCV prevalence and treatment cost/outcomes, factors which are changing quickly due to the 
dramatic recent progress in the HCV treatment landscape. Continued monitoring and updating the 
economic analyses as part of implementation will be important to ensure screening remains cost-
effective in this population. 
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